"Multiprofile Hospital for Active Treatment of Neurology and Psychiatry - Sveti Naum" EAD - Neurology Clinic for Movement Disorders
Welcome,         Profile    Billing    Logout  
 84 Trials 
84 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Investigator, Principal
COVID-PACT, NCT04409834: Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial

Recruiting
4
750
US
Unfractionated Heparin IV, Enoxaparin 1 mg/kg, Clopidogrel, Unfractionated heparin SC, Enoxaparin 40 Mg/0.4 mL Injectable Solution
The TIMI Study Group
COVID-19, Venous Thromboembolism, Arterial Thrombosis
11/21
11/21
NCT04248205: Ketamine for Post-operative Analgesia in Hemorrhoidectomy

Recruiting
4
100
US
Ketamine
University of Oklahoma
Hemorrhoids
01/22
07/22
NCT04790279: Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension

Recruiting
4
160
US
Amlodipine, NIFEdipine ER
Prisma Health-Upstate
Hypertension in Pregnancy
10/22
10/22
NCT04459377 / 2014-004235-39: Ketamine Analgesia in Third Molar Surgery

Recruiting
4
165
Europe
S-Ketamine, Sodium Chloride 0.9% Inj
Dalarna County Council, Sweden, Uppsala University, Center for Clinical Research Dalarna, Sweden
Pain, Postoperative
12/22
12/23
OCEAN, NCT04986982: OpiCapone Effect on Motor Fluctuations and pAiN

Recruiting
4
140
Europe
Opicapone 50 mg, BIA 9-1067, Matching placebo
Bial - Portela C S.A.
Parkinson Disease
12/22
12/22
PLX3397, NCT04526704 / 2020-000192-20: Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib

Recruiting
4
35
Europe, US, RoW
Pexidartinib, TURALIO™️, PLX3397
Daiichi Sankyo, Inc.
Tenosynovial Giant Cell Tumor
04/23
04/23
POUR, NCT04994431: Post-Operative Urinary Retention () in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin

Not yet recruiting
4
60
US
Tamsulosin Hydrochloride
Feiran Lou, UMass Memorial Health Care
Thoracic Diseases, Urinary Retention
06/23
12/23
VALO-2, NCT04520750: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita

Recruiting
3b
90
US
PTX-022
Palvella Therapeutics, Inc.
Pachyonychia Congenita
12/21
12/21
S31PK/PD, NCT02563327: Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

Recruiting
3
60
RoW
Rifapentine, Priftin, Moxifloxacin, Rifampin, Isoniazid, Pyrazinamide, Ethambutol, Pyridoxine, Vitamin B6
Centers for Disease Control and Prevention, AIDS Clinical Trials Group
Tuberculosis
03/19
03/20
NCT03395639 / 2017-000475-90: Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease

Recruiting
3
168
Europe, Canada, US, RoW
Edoxaban, Lixiana, Savaysa, Standard of Care (SOC), Warfarin/heparin, Enoxaparin
Daiichi Sankyo, Inc.
Cardiac Disease
12/21
12/21
TROPION-LUNG01, NCT04656652 / 2020-004643-80: Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations

Checkmark [VIRTUAL] TROPION-PanTumor01: Dose analysis of the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062) for the treatment (Tx) of advanced or metastatic non-small cell lung cancer (NSCLC).
Checkmark [VIRTUAL] A randomized, phase 3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (TROPION-Lung01).
Recruiting
3
590
Europe, Canada, Japan, US, RoW
DS-1062a, Datopotamab deruxtecan (Dato-DXd), Docetaxel
Daiichi Sankyo, Inc., AstraZeneca
Non-small Cell Lung Cancer
10/22
06/24
NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

Recruiting
3
300
Europe, Canada, US, RoW
Macitentan, ACT-064992, Standard-of-care
Actelion
Pulmonary Arterial Hypertension
12/22
12/22
NCT04516967 / 2020-003232-24: Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months

Recruiting
3
72
Europe, US, RoW
Avatrombopag, Doptelet, Placebo
Dova Pharmaceuticals
Immune Thrombocytopenia
05/23
05/25
DESTINY-Gastric04, NCT04704934 / 2020-004559-34: Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen

Hourglass Sep 2021 - Sep 2021 : Data from DESTINY-Gastric04 trial for HER2 Positive Gastric Cancer (GC) or GEJ at ESMO 2021
Checkmark First patient was dosed in DESTINY-Gastric04 in patients with HER2 positive gastric or GEJ adenocarcinoma
Checkmark [VIRTUAL] Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen (DESTINY-gastric04, DG-04): A randomized p…
Recruiting
3
490
Europe, Japan, RoW
Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel
Daiichi Sankyo, Inc., AstraZeneca
Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
04/24
11/24
TNX-N, NCT03503136: Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC

Not yet recruiting
3
632
RoW
docetaxel, nedaplatin, and capecitabine, TNX induction chemotherapy, nedaplatin, N, docetaxel, cisplatin, and fluorouracil, TPF induction chemotherapy, cisplatin, P, docetaxel, cisplatin, and capecitabine, TPX induction chemotherapy, docetaxel, nedaplatin, and fluorouracil, TNF induction chemotherapy
Sun Yat-sen University, Tongji Hospital, Wuhan Union Hospital, China, Peking University, Fourth Military Medical University, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Guangdong Pharmaceutical University, First People's Hospital of Foshan, Fifth Affiliated Hospital, Sun Yat-Sen University, Cancer Hospital of Guizhou Province, Xiangya Hospital of Central South University, Jilin Provincial Tumor Hospital, Henan Cancer Hospital, Hunan Cancer Hospital, Cancer Hospital of Guangxi Medical University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
06/24
06/26
DESTINY-Breast05, NCT04622319 / 2020-003982-20: A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy

Checkmark Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05)
Recruiting
3
1600
Europe, Canada, Japan, US, RoW
DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1)
Daiichi Sankyo, Inc., AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI)
HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
12/25
09/27
NCT04341116: Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)

Recruiting
2/3
384
US
TJ003234, Placebo
I-Mab Biopharma Co. Ltd.
Coronavirus Disease 2019 COVID-19
12/21
12/21
KPL-716-C201, NCT03816891 / 2020-004198-38: Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

Recruiting
2a/b
230
Canada, US
vixarelimab, KPL-716, Placebo
Kiniksa Pharmaceuticals, Ltd.
Prurigo Nodularis, Pruritis
02/22
03/23
NCT03190824: Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma

Active, not recruiting
2a
4
US
OBP-301, Telomelysin
Syneos Health, Oncolys BioPharma Inc
Melanoma Stage III, Melanoma Stage Iv
06/21
10/21
LOMBARD, NCT04583358 / 2020-000047-31: Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis

Recruiting
2a
102
Europe, Canada, US, RoW
AMT-101 (oral), Placebo (oral)
Applied Molecular Transport
Ulcerative Colitis
06/22
06/22
NCT03351777: Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis

Recruiting
2
120
US
PR022
Realm Therapeutics, Inc.
Atopic Dermatitis
04/18
07/18
AAVIATE, NCT04514653: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Recruiting
2
40
US
RGX-314 Dose 1, RGX-314 Dose 2, Ranibizumab (LUCENTIS®)
Regenxbio Inc.
Neovascular Age-Related Macular Degeneration (nAMD)
02/21
02/22
AVENuE, NCT03617666: Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study

Recruiting
2
47
Europe
Avelumab
University College, London, Pfizer
Hodgkin Lymphoma
10/21
11/24
CLIN-011, NCT04739423: A Study of CST-103 Co-administered With CST-107 in Subjects With Neurodegenerative Disorders

Recruiting
2
40
Europe, RoW
CST-103, CST-107, matching placebo
CuraSen Therapeutics, Inc.
Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia
12/21
03/22
NCT04419649: A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Recruiting
2
54
RoW
KER-050
Keros Therapeutics
Myelodysplastic Syndromes, Cytopenia
01/22
07/22
NCT04316143 / 2018-002448-10: Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH

Recruiting
2
32
Europe
Zamicastat, BIA 5-1058
Bial - Portela C S.A.
Pulmonary Arterial Hypertension
03/22
03/22
FILLMORE, NCT04741087: Study of the Safety and Efficacy of AMT-101 in Subjects With Pouchitis

Recruiting
2
20
Europe, Canada, US
AMT-101 (oral)-Dose A, AMT-101 (oral)-Dose B
Applied Molecular Transport
Pouchitis
03/22
06/22
NCT04935762: A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012)

Not yet recruiting
2
25
RoW
CST-103, CST-107, matching placebo
CuraSen Therapeutics, Inc.
Freezing of Gait Symptoms in Parkinson's Disease
09/22
12/22
DESTINY-CRC02, NCT04744831 / 2020-004782-39: Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer

Checkmark [VIRTUAL] Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).
Recruiting
2
120
Europe, Japan, US, RoW
DS-8201a 5.4 mg/kg Q3W, T-DXd, DS-8201a 6.4 mg/kg Q3W
Daiichi Sankyo, Inc., AstraZeneca, Syneos Health
Advanced Colorectal Cancer
02/23
08/23
NCT04479436: A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer

Checkmark [VIRTUAL] An open-label, phase II study of patritumab deruxtecan (HER3-DXd, U3-1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC).
Checkmark [VIRTUAL] An open-label, phase 2 study of patritumab deruxtecan in patients with previously treated advanced/metastatic colorectal cancer
Recruiting
2
80
Europe, Japan, US
U3-1402
Daiichi Sankyo, Inc.
Metastatic Colorectal Cancer
02/23
05/23
DESTINY-LUNG02, NCT04644237 / 2020-003427-42: Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

Hourglass Sep 2021 - Sep 2021 : Data from DESTINY-Lung02 trial for HER2-positive, first-line metastatic NSCLC at ESMO 2021
Checkmark First patient dosed in DESTINY-Lung02 trial in 2L HER2 mutated NSCLC
Checkmark [VIRTUAL] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): A phase (ph) II study (DESTINY-Lung02)
Recruiting
2
150
Europe, Canada, Japan, US, RoW
Trastuzumab deruxtecan
Daiichi Sankyo, Inc., AstraZeneca
Non-Small Cell Lung Cancer
03/23
09/23
TROPION-Lung05, NCT04484142 / 2020-002774-27: Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations

Checkmark [VIRTUAL] Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study
Checkmark [VIRTUAL] A Phase 2 Study of Datopotamab Deruxtecan (Dato - DXd) in Advanced NSCLC With Actionable Genomic Alterations (TROPION - Lung05)
Recruiting
2
150
Europe, Japan, US, RoW
DS-1062a, Datopotamab Deruxtecan
Daiichi Sankyo, Inc., AstraZeneca
Non-small Cell Lung Cancer
03/23
05/24
StrataSOMA, NCT04765202: StrataGraft Overlay of Meshed Autograft in Full-thickness Thermal Burns

Recruiting
2
40
US
AG Tx, Meshed Autograft, SOMA Tx, StrataGraft skin tissue Overlay of Meshed Autograft (SOMA)
Stratatech, a Mallinckrodt Company
Full Thickness Burn
06/23
06/23
HERTHENA-Lung01, NCT04619004: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Checkmark [VIRTUAL] Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).
Checkmark [VIRTUAL] HERTHENA-Lung01: A randomized phase 2 study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC.
Recruiting
2
420
Europe, Japan, US, RoW
Patritumab Deruxtecan (Fixed dose), U3-1402, HER3-DXd, Patritumab Deruxtecan (Up-Titration)
Daiichi Sankyo, Inc., Daiichi Sankyo Co., Ltd.
Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
11/23
07/24
NCT04703192 / 2020-004954-31: Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

Checkmark [VIRTUAL] FIRST-IN-HUMAN STUDY OF THE EZH1 AND EZH2 DUAL INHIBITOR VALEMETOSTAT TOSYLATE (DS-3201B) IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS
Recruiting
2
176
Canada, Japan, US, RoW
Valemetostat Tosylate, DS-3201b
Daiichi Sankyo, Inc., DAIICHI SANKYO, INC.
Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma
12/23
03/26
NCT04870905: Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma

Not yet recruiting
2
100
RoW
Tis-U-Sol
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Nasopharyngeal Neoplasms
05/24
05/26
GCT3013-01, NCT03625037 / 2017-001748-36: GEN3013 Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

Checkmark Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.
Checkmark Updated data from trial for r/r DLBCL and follicular lymphoma
Checkmark [VIRTUAL] Subcutaneous Epcoritamab in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma: Safety Profile and Anti-tumor Activity
Checkmark [VIRTUAL] SUBCUTANEOUS EPCORITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA: SAFETY PROFILE AND ANTI-TUMOR ACTIVITY
Checkmark [VIRTUAL] Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity.
More
Recruiting
1/2
486
Europe, Canada, US, RoW
Epcoritamab
Genmab, AbbVie
Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma
01/22
12/25
NCT04145622: Study of DS-7300a in Participants With Advanced Solid Malignant Tumors

Checkmark [VIRTUAL] A phase I/II multicenter, first-in-human study of DS-7300 (B7-H3 DXd-ADC) in patients (pts) with advanced solid tumors
Checkmark [VIRTUAL] DS-7300a, a novel B7-H3-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, exhibits potent anti-tumor effects in nonclinical models
Checkmark [VIRTUAL] A phase I/II, two-part, multicenter, first-in-human study of DS-7300a in patients with advanced solid malignant tumors.
Recruiting
1/2
180
Japan, US
DS-7300a
Daiichi Sankyo Co., Ltd.
Advanced Solid Tumor, Malignant Solid Tumor
03/23
10/23
NCT03520075 / 2018-004568-72: Study of ASTX029 in Subjects With Advanced Solid Tumors

Checkmark ASTX029, a Novel Dual-Mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK.
Checkmark [VIRTUAL] Immune modulation by the dual-mechanism ERK inhibitor, ASTX029, in MAPK-activated tumor models
Checkmark [VIRTUAL] A first-in-human, Phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors
Checkmark [VIRTUAL] Anti-Tumor Activity of ASTX029, a Dual Mechanism Inhibitor of ERK1/2, in Preclinical AML Models
Checkmark [VIRTUAL] Combined inhibition of SHP2 and ERK enhances anti-tumour effects in preclinical models
More
Recruiting
1/2
300
Europe, US
ASTX029
Astex Pharmaceuticals, Inc., Astex Pharmaceuticals, Inc.
Solid Tumor, Adult
06/23
12/23
NCT03793478 / 2016-002919-18: Safety and Effectiveness of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Checkmark A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML)
Recruiting
1/2
65
Europe, Canada, US, RoW
Quizartinib, Quizartinib dihydrochloride, Vanflyta, Intrathecal (IT) triple chemotherapy prophylaxis, Fludarabine, Cytarabine, Etoposide
Daiichi Sankyo, Inc., Innovative Therapies For Children with Cancer Consortium, Children's Oncology Group
Acute Myeloid Leukemia
05/27
05/27
KEYNOTE KN-797, NCT04042701: DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

Checkmark [VIRTUAL] Trastuzumab Deruxtecan Plus Pembrolizumab in Advanced/Metastatic Breast or Non-Small Cell Lung Cancer: A Phase 1b Study
Checkmark [VIRTUAL] Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC): A phase Ib, multicenter, study.
Recruiting
1b
115
Europe, US
Trastuzumab deruxtecan (DS-8201a), Pembrolizumab
Daiichi Sankyo, Inc., AstraZeneca UK Limited, Merck Sharp & Dohme Corp.
Breast Cancer, Non-small Cell Lung Carcinoma
08/22
05/23
KEYNOTE KN-B43, NCT04526691: Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

Checkmark [VIRTUAL] TROPION - Lung02: Datopotamab Deruxtecan (Dato - DXd) Plus Pembrolizumab and Platinum - Based Chemotherapy in Advanced NSCLC
Recruiting
1b
120
Europe, Japan, US, RoW
Datopotamab deruxtecan, Dato-DXd, Pembrolizumab, Carboplatin, Cisplatin
Daiichi Sankyo, Inc., AstraZeneca, Merck Sharp & Dohme Corp.
Advanced or Metastatic NSCLC
12/22
10/24
TROPION-Lung04, NCT04612751: Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer

Checkmark [VIRTUAL] TROPION - Lung04: Datopotamab Deruxtecan (Dato - DXd) Plus Durvalumab and Platinum - Based Chemotherapy in Advanced NSCLC
Recruiting
1b
120
Europe, Japan, US
Datopotamab deruxtecan, Dato-DXd, Durvalumab, Carboplatin, Cisplatin
Daiichi Sankyo, Inc., AstraZeneca
Advanced or Metastatic NSCLC
03/23
12/24
NCT03468751: Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors

Recruiting
1
30
RoW
HLX10, anti-PD-1 monoclonal antibody
Henlix, Inc
Solid Tumor
06/20
08/20
SQ3370-001, NCT04106492: Phase 1 Study of SQ3370 in Patients With Advanced Solid Tumors

Checkmark [VIRTUAL] Phase 1 trial of SQ3370 in solid tumors
Checkmark [VIRTUAL] The CAPAC Platform maximizes therapeutic benefit and reduces systemic cytotoxic exposure in small and large animals
Checkmark [VIRTUAL] SQ3370-001 is a multi-center open-label phase I dose-escalation study to test a novel intratumoral and systemic approach to treat advanced solid tumors
Checkmark [VIRTUAL] SQ3370-001 is a multi-center open-label phase I dose-escalation study to test a novel intratumoral and systemic approach to treat advanced solid tumors
Checkmark [VIRTUAL] Effect of local activation via SQ3370 on the safety of chemotherapy with concomitant anti-tumor immune response.
More
Recruiting
1
40
US, RoW
SQ3370
Shasqi, Inc.
Cancer
08/21
08/23
NCT04099771: Ketamine for Mood Disorders With Suicidal Ideation

Recruiting
1
20
US
Ketamine
The Miriam Hospital
Depressive Disorder, Major, Suicidal Ideation
12/21
12/21
NCT04894110: Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema

Recruiting
1
18
US
EO2002
Emmecell
Corneal Edema, Corneal Endothelial Dysfunction, Corneal Endothelial Dystrophy, Fuchs Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Bullous Keratopathy, Endothelial Dysfunction, Moderate Corneal Endothelial Decompensation
12/22
06/23
NCT04707248: A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

Checkmark [VIRTUAL] DS-6000a, a novel CDH6-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, demonstrates potent antitumor activity in preclinical models
Recruiting
1
102
US
DS-6000a
Daiichi Sankyo, Inc.
Renal Cell Carcinoma, Ovarian Tumor
02/23
02/23
ICVP, NCT04634383: A Phase I Feasibility Study of an Intracortical Visual Prosthesis () for People With Blindness

Recruiting
1
5
US
WFMA - wireless floating microelectrode array, ICVP System, ICVP, Intracortical Visual Prosthesis
Illinois Institute of Technology, National Institute of Neurological Disorders and Stroke (NINDS), Rush University Medical Center, The Chicago Lighthouse, The University of Texas at Dallas, University of Chicago, Johns Hopkins University
Ocular Injury, Optic Nerve Diseases, Photoreceptor Degeneration, Blindness,Acquired
08/23
08/23
TROPION-PanTumor01, NCT03401385: First-in-human Study of DS-1062a for Advanced Solid Tumors

Checkmark [VIRTUAL] Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study
Checkmark [VIRTUAL] TROPION - PanTumor01: Updated Results From the NSCLC Cohort of the Phase 1 Study of Datopotamab Deruxtecan in Solid Tumors
Checkmark [VIRTUAL] TROPION-PanTumor01: Dose analysis of the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062) for the treatment (Tx) of advanced or metastatic non-small cell lung cancer (NSCLC).
Checkmark [VIRTUAL] BEGONIA: Phase 1b/2, open-label, platform study of the safety and efficacy of durvalumab (D) ± paclitaxel (P) with novel oncology therapies for first‑line metastatic triple-negative breast cancer (mTNBC): Addition of arm 7, D + datopotamab der...
Checkmark [VIRTUAL] Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase 1 trial
More
Recruiting
1
770
Japan, US
DS-1062a, Study treatment
Daiichi Sankyo Co., Ltd., Daiichi Sankyo, Inc., AstraZeneca
Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer
01/24
01/24
NCT04676477: Patritumab Deruxtecan in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Recruiting
1
252
Japan, US
Patritumab deruxtecan, U3-1402, HER3-DXd, Osimertinib
Daiichi Sankyo, Inc.
Non-Small Cell Lung Cancer (NSCLC)
01/24
01/24
NCT02454296: Paracervical Block for Pain Associated With Laminaria Insertion

Checkmark Paracervical Block for Laminaria Insertion Before Second-Trimester Abortion: A Randomized Controlled Trial.
Recruiting
N/A
40
US
Paracervical Block with lidocaine, Paracervical block, Sham paracervical block, Sham block; placebo
University of Hawaii
Pain
12/15
12/15
NCT03379168: Efficacy of Micro-fragmented Adipose Tissue Injection for Knee Osteoarthritis.

Recruiting
N/A
100
US
Microfragmented Adipose Tissue (Lipogems), Corticosteroid injection, Saline
Dustin L. Richter, MD
Knee Osteoarthritis
03/19
07/19
MNH, NCT01073475: Maternal Newborn Health Registry

Checkmark Stillbirth 2010-2018: a prospective, population-based, multi-country study from the Global Network.
Checkmark Neonatal deaths in rural Karnataka, India 2014-2018: a prospective population-based observational study in a low-resource setting.
Checkmark The Global Network Maternal Newborn Health Registry: a multi-country, community-based registry of pregnancy outcomes.
Checkmark Evaluating the effect of care around labor and delivery practices on early neonatal mortality in the Global Network's Maternal and Newborn Health Registry.
Checkmark The relationship between birth intervals and adverse maternal and neonatal outcomes in six low and lower-middle income countries.
More
Recruiting
N/A
750000
US, RoW
There is no intervention associated with this study.
NICHD Global Network for Women's and Children's Health
Pregnancy Outcome Trends in Low-resource Geographic Areas
05/20
05/20
B-Free, NCT03928236: Benzodiazepine-free Cardiac Anesthesia for Reduction of Postoperative Delirium

Recruiting
N/A
15886
Canada
Limited Intraoperative Benzodiazepine, Liberal Intraoperative Benzodiazepine
Population Health Research Institute
Delirium, Post-cardiac Surgery
06/21
12/21
NCT03984058: Recruitment Strategies Comparing Different Strategies in Sleep Apnea and Prediabetes

Recruiting
N/A
60
US
Lifestyle Intervention
Johns Hopkins University, Fusion Health
Sleep Disorder, Pre Diabetes, Obstructive Sleep Apnea
11/21
11/21
NCT03866707: Epigenetic and Metabolomic Changes in Childhood Cancer Survivors

Recruiting
N/A
16
US
One-time blood draw, Evaluation of CpG methylation, Metabolomic analysis
Wake Forest University Health Sciences
Childhood Cancer
12/21
12/21
ACAB, NCT04292405: Accuracy of Cardiac Acoustic Biomarkers Recorded by the Wearable Cardioverter Defibrillator

Recruiting
N/A
60
US
Wearable Cardioverter Defibrillator, AUDICOR AM
Zoll Medical Corporation
Heart Failure
12/21
01/22
NCT05025722: Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings

Recruiting
N/A
48
US
Non Interventional
Daiichi Sankyo, Inc., PXE International, Thomas Jefferson University
Pseudoxanthoma Elasticum
01/22
01/22
NCT04886544: Clinical Study to Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 720 Injected for Jawline Contouring

Not yet recruiting
N/A
72
Europe
YVOIRE Y-Solution 720
LG Chem
Jaw Volume Deficit
03/22
12/22
NCT04927052: A Study to Evaluate the Safety and Efficacy of Revanesse Shape + With Lidocaine Versus Juvederm Voluma With Lidocaine for the Correction of Age-Related Midface Volume Deficit / Lipoatrophy at 6 and 12 Months Post-treatment

Recruiting
N/A
140
Canada
Revanesse Shape + with Lidocaine, Juvederm Voluma with Lidocaine.
Prollenium Medical Technologies Inc.
Volume Deficit in the Mid-face
05/22
03/23
NCT02945085: 3D Team Care for Cognitively Vulnerable Older Adults

Checkmark Pharmacist Identification of Medication Therapy Problems Involving Cognition Among Older Adults Followed by a Home-Based Care Team.
Recruiting
N/A
956
US
Home Based Care Team, Telephone Based Care Team
UConn Health, Patient-Centered Outcomes Research Institute, University of Connecticut
Dementia, Depression, Delirium
05/22
05/22
NCT04604340: Radial Versus Femoral Arterial Access for Cerebral Angiography in Adolescents

Recruiting
N/A
56
Canada
transradial access for neuroangiography, transfemoral access for neuroangiography
The Hospital for Sick Children
Procedural Related Injuries and Complications Nec, Patient Satisfaction
07/22
07/23
NCT03586414: MitoQ Supplementation and Cardiovascular Function in Healthy Men and Women

Recruiting
N/A
60
US
MITOQUINOL MESYLATE then placebo, MitoQ, Mitoquinol methanesulfonate, Placebo, then MITOQUINOL MESYLATE
University of Colorado, Denver, University of Colorado Nutrition Obesity Research Center (NORC)
Diastolic Dysfunction
07/22
08/22
NCT04507425: High Flow Nasal Cannula With Noninvasive Ventilation

Recruiting
N/A
1770
US
Standard of Care - Nasal Cannula, High-flow nasal cannula, HFNC, HFNC plus non-invasive ventilation
University of Oklahoma
Acute Respiratory Failure
07/22
09/22
TMSVS, NCT04925232: Transcranial Magnetic Stimulation For Visual Snow Syndrome

Checkmark A Study Protocol for an Open-Label Feasibility Treatment Trial of Visual Snow Syndrome With Transcranial Magnetic Stimulation.
Recruiting
N/A
10
US
Transcranial Magnetic Stimulation device, TMS
University of Colorado, Denver
Visual Snow Syndrome
11/22
11/22
ENCOURAGE-AF, NCT04519944: Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Recruiting
N/A
1200
Europe
Edoxaban
Daiichi Sankyo, Inc., Daiichi Sankyo Deutschland GmbH
Non-valvular Atrial Fibrillation
12/22
12/22
NCT04622969: The Healthy Child Development Program Study

Recruiting
N/A
60
US
Healthy Child Development Program
University of South Carolina
Child Behavior, Child Health, Child, Preschool, Parents
12/22
02/23
NCT04625660: Detour2 Continued Access Study

Recruiting
N/A
70
US
PQ Bypass System
PQ Bypass, Inc.
Peripheral Artery Diseases
01/23
01/24
NCT04049591: Higher vs. Lower Dose Heparin for PCI

Not yet recruiting
N/A
16000
Canada
Higher Dose UFH, Lower Dose UFH
Population Health Research Institute
Cardiovascular Diseases, Percutaneous Coronary Intervention
01/23
05/23
NCT04931251: Addressing Cancer-Related Financial Toxicity in Rural Oncology Care Settings

Not yet recruiting
N/A
780
US
Financial Navigation
UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI)
Neoplasms, Carcinoma
01/23
07/23
BHmApp, NCT04074044: Evaluation of a New Bladder Health Mobile Application in Pregnancy

Recruiting
N/A
30
US
BHmApp
William Beaumont Hospitals, University of Pennsylvania
Urinary Incontinence
02/23
02/24
PAROS, NCT04745520: Randomized Clinical Trial of Rib Fixation Versus Medical Analgesia in Uncomplicated Rib Fractures on Pain Control.

Recruiting
N/A
102
Europe
Rib fixation, Analgesia
Benoît Bédat, Centre Hospitalier Universitaire Vaudois, Hôpital du Valais
Rib Fractures
03/23
03/24
PULSE, NCT04828304: PLASOMA Ultimate Safety & Efficacy Study

Recruiting
N/A
100
Europe
PLASOMA
Plasmacure, Diabetes Fonds, Pathology and Medical Microbiology
Diabetic Foot Ulcer, Venous Leg Ulcer, Pressure Ulcer, Burn Wound, Skin Graft, Infected Surgical Wound, Skin Flap
04/23
04/23
NCT03929731: Long-term Outcomes, Recurrence Rates, and Treatment Needs in Polypoidal Choroidal Vasculopathy (PCV)

Recruiting
N/A
72
RoW
Indocyanine Green Angiography, Optical Coherence Tomography-Angiography, Fundus photography, Fundus fluorescein, Optical Coherence Tomography
Singapore National Eye Centre
Polypoidal Choroidal Vasculopathy
06/23
06/23
NCT04910048: Impact of a POPOP on Preoperative Health, Eligibility, and Clinical & Patient-Reported Outcomes in TJA

Not yet recruiting
N/A
70
US
POPOP (preoperative patient optimization program), 20Lighter, SOC (standard of care)
University of Arkansas
Osteoarthritis, Knee, Osteoarthritis, Hip, Avascular Necrosis, Rheumatoid Arthritis
10/23
10/23
MEE, NCT04730700: Evaluation of Multi-Tined Expandable Electrode () Efficacy and Safety in Treatment of Lumbar Facet Arthropathy by Radiofrequency Neurotomies Compared to Conservative Medical Management.

Recruiting
N/A
50
US
Radiofrequency Ablation with MEE, Conventional Medical Management
University of Kansas Medical Center
Chronic Low-back Pain
11/23
11/23
RELIEF, NCT04100135: GORE® CARDIOFORM Septal Occluder Migraine Clinical Study

Recruiting
N/A
150
US
Actual device PFO closure, GORE® CARDIOFORM Septal Occluder, Thienopyridine (clopidogrel or prasugrel), Plavix, Effient, Sham device PFO closure
W.L.Gore & Associates
Migraine, Patent Foramen Ovale
03/24
06/26
ETNA-AF-CHINA, NCT04747496: Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China

Recruiting
N/A
5000
RoW
Edoxaban
Daiichi Sankyo, Inc., Daiichi Sankyo (China) Holdings Co., Ltd.
Non-valvular Atrial Fibrillation
08/24
08/24
MILOS, NCT04579367: Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia

Recruiting
N/A
5000
Europe
Bempedoic acid and/or its fixed-dose combination with ezetimibe
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Hypercholesterolemia, Mixed Dyslipidemia
09/24
09/24
NCT04258280: Improving Genetic Counseling for BRCA+ Mothers

Recruiting
N/A
200
US
Education and counseling, Education
Georgetown University
Breast Cancer
12/24
12/25
NCT03843190: Healthy Me: A Program for Older Women

Recruiting
N/A
240
US
Take of Pounds Sensibly (TOPS)
Duke University
Obesity
03/25
03/25
NCT04635111: A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment

Recruiting
N/A
30
US
TURALIO™
Daiichi Sankyo, Inc.
Hepatotoxicity, Tenosynovial Giant Cell Tumor
06/25
03/36
NCT04445207: Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19

Available
N/A
US
Convalescent Plasma
Jonathan Gerber
COVID, Sars-CoV2, Corona Virus Infection
 
 

Download Options